Recent SEC filings disclose management changes, clinical trial updates, and financial results through late 2025. No recent public news coverage is available.

• Rami Levin was appointed Chief Executive Officer effective January 1, 2026, and Lynne Kelley was appointed Chief Medical Officer effective March 2, 2026, with detailed employment agreements disclosed [S1].
• Topline data from a Phase II clinical trial of Berubicin in Glioblastoma Multiforme patients showed clinically relevant outcomes comparable to Lomustine but no statistically significant improvement in overall survival; the company is evaluating potential next steps in consultation with the FDA [S1].
• As of December 31, 2025, the company reported cash and equivalents of approximately $7.2 million, current assets of $8.1 million, current liabilities of $4.1 million, a current ratio of 1.98, and a net loss of $15.85 million for the fiscal year [S1].
• The company has historically funded operations through equity sales and estimates sufficient working capital into the second half of 2026, assuming initiation of a TPI 287 trial and completion of the Berubicin trial [S2].
• The company is subject to Nasdaq listing requirements and has experienced past non-compliance with minimum bid price and stockholders’ equity requirements but is currently in compliance and under a Mandatory Panel Monitor until March 31, 2026 [S2].

CNS Pharmaceuticals has developed two drug candidates, TPI 287 and Berubicin, that address the challenging treatment landscape of CNS tumors by crossing the blood-brain barrier. The Orphan Drug Designations for both compounds provide potential regulatory exclusivity that could protect market share if approved. Early clinical data suggest TPI 287 may overcome drug resistance mechanisms common in CNS cancers. The company’s focused pipeline and intellectual property rights position it to potentially offer new therapeutic options for Glioblastoma patients, a population with limited effective treatments. Recent management appointments with industry experience may support execution of clinical development and regulatory strategies.

The company is in the clinical development stage with no approved products and has reported net losses and negative earnings per share, reflecting ongoing operating expenses and investment in trials. The Phase II trial for Berubicin did not demonstrate a statistically significant improvement in overall survival, the primary endpoint, which raises uncertainty about regulatory approval and commercial viability. CNS Pharmaceuticals depends on external financing to fund operations and clinical trials, with no assurance of securing sufficient capital on favorable terms. The company lacks manufacturing and sales infrastructure, relying on third parties, which may pose operational risks. Additionally, the company faces risks related to regulatory approvals, market acceptance, competition, and intellectual property challenges.

CNS Pharmaceuticals' moat is primarily based on its proprietary drug candidates designed to cross the blood-brain barrier, a significant challenge in treating CNS malignancies. The company holds exclusive licenses and intellectual property rights for TPI 287 and Berubicin, both granted Orphan Drug Designation by the FDA, which may provide market exclusivity and strengthen patent protections. The specialized nature of these compounds and their potential to address unmet medical needs in Glioblastoma and other CNS cancers contribute to the company's competitive positioning. However, the company relies on third-party manufacturing and lacks commercial infrastructure, which may limit its ability to scale independently. The clinical-stage status and ongoing development risks also temper the strength of the moat at this stage.

• Financing Risk: The company requires additional capital to fund clinical trials and operations. Failure to secure financing could necessitate scaling back or ceasing operations.
• Regulatory Approval Risk: Approval of drug candidates depends on successful clinical trial outcomes and regulatory review, which are uncertain and may delay or prevent commercialization.
• Clinical Development Risk: Clinical trials may not demonstrate safety or efficacy sufficient for approval, as seen with Berubicin's Phase II trial lacking statistically significant survival benefit.
• Market Acceptance Risk: Even if approved, patients and physicians may not adopt the company’s therapies, especially given administration routes differing from current standards.
• Manufacturing and Supply Risk: The company outsources manufacturing and lacks internal production capabilities, creating dependency on third parties for supply continuity and quality.
• Intellectual Property Risk: While holding licenses and Orphan Drug Designations, patent expirations and challenges could affect exclusivity and competitive positioning.
• Listing Compliance Risk: The company has experienced past non-compliance with Nasdaq listing requirements, and future failures could lead to delisting, affecting liquidity and financing.

• CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing anti-cancer drug candidates for brain and central nervous system (CNS) tumors.
• The company’s primary drug candidates are TPI 287, an abeotaxane taxane derivative designed to cross the blood-brain barrier (BBB), and Berubicin, an anthracycline chemotherapy agent also designed to cross the BBB.
• TPI 287 has received Orphan Drug Designation (ODD) from the FDA, which may provide 7 years of market exclusivity upon approval.
• TPI 287 has been studied in Phase I and II clinical trials in over 300 patients for indications including Glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma.
• Berubicin was discovered at The University of Texas M.D. Anderson Cancer Center and licensed through various agreements; it also has FDA Orphan Drug Designation for malignant gliomas.
• A Phase II clinical trial comparing Berubicin to Lomustine in Glioblastoma Multiforme patients who failed first-line therapy showed Berubicin produced clinically relevant outcomes comparable to Lomustine but did not demonstrate a statistically significant difference in overall survival, the primary endpoint.
• The company is evaluating potential paths forward for Berubicin in consultation with the FDA.
• CNS Pharmaceuticals does not have manufacturing facilities or a sales organization; all manufacturing is outsourced to third parties.
• The company holds exclusive licenses and intellectual property rights related to TPI 287 and Berubicin, including agreements with Cortice Biosciences and Reata Pharmaceuticals.
• Financial snapshot as of December 31, 2025: cash and equivalents of approximately $7.2 million, current assets of $8.1 million, current liabilities of $4.1 million, resulting in a current ratio of 1.98 and a cash ratio of 1.76.
• Net loss for fiscal year 2025 was approximately $15.85 million with basic and diluted EPS of -$35.75 per share.
• The company has historically funded operations through equity sales and expects to require additional financing to support clinical trials and operations.
• Recent management changes include appointment of Rami Levin as CEO in January 2026 and Lynne Kelley as Chief Medical Officer in March 2026.
• The company is subject to Nasdaq Capital Market listing requirements and has experienced past non-compliance with minimum bid price and stockholders’ equity requirements but is currently in compliance.
• Risks include the need for additional financing, regulatory approval uncertainties, clinical trial outcomes, market acceptance of drug candidates, competition, intellectual property protection, and dependency on third-party manufacturers.